louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02211053: Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial
Official title: Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Brain Dead Organ Donors
Keywords: Organ donation
Brain dead
Levothyroxine
Lead sponsor: Hopital du Sacre-Coeur de Montreal
Sponsor class: OTHER
First posted: 2014-08-07
Enrollment: 15
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The primary objective of this study is to evaluate the feasibility of a randomized controlled trial comparing levothyroxine to placebo in neurologically deceased donors


Eligibility criteria: Inclusion Criteria:

* Prior signed written informed from family member (no more needed following amendment in July 2016)
* 16 years of age or older
* Brain death diagnosis
* Left ventricular ejection fraction \< 50% determined by transthoracic echocardiography or hemodynamic instability defined as a mean dose of noradrenaline 0.1 mcg/kg/min + vasopressin

Exclusion Criteria:

* Heart failure history (removed after june 2015)
* Chronic exogenous oral T4 or T3 before death (removed after june 2015)
* Having received T4 infusion before recruitment(removed after june 2015)
* Echographic images not interpretable

  * Age 75 and older(removed after june 2015)
  * Prior coronary heart disease defined as prior coronary artery bypass graft or percutaneous coronary intervention (with or without stents)(removed after june 2015)

Primary outcomes:
measure: Study feasibility
timeFrame: In 2 years
measure: Variation in left ventricular ejection fraction
timeFrame: 6 hours post infusion
Secondary outcomes:
measure: Numbers of donated hearts
timeFrame: On organ donation surgery
measure: Incidence of de novo atrial fibrillation
timeFrame: From beginning of infusion until beginning of retrieval surgery
measure: Time from recruitment to the administration of the study drug
timeFrame: From randomization to 12 hours post randomization
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Hopital du Sacré-Coeur de Montreal
state: Quebec
Study officials:
affiliation: Hopital du Sacre-Coeur de Montreal
name: Anne Julie Frenette, M.Sc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Frenette AJ, Williamson D, Williams V, Lagace AM, Charbonney E, Serri K. A Pilot Randomized Controlled Trial Comparing Levothyroxine to Placebo in Neurologically Deceased Donors. Prog Transplant. 2019 Sep;29(3):261-268. doi: 10.1177/1526924819855083. Epub 2019 Jun 9.
Clinical trial NCT03535753: Safety and Efficacy Evaluation of Decitabine With R-GDP
Official title: Safety and Efficacy Evaluation of Decitabine With R-GDP on Refractory or Relapsed NHL Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: NHL
Lead sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-05-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Assessment of the Safety and efficacy of Administering decitabin plus R-GDP to NHL patients

Detailed description: RR NHL patients will be treated with decitabin plus R-GDP , safety and efficacy will be assessed.

Eligibility criteria: Inclusion Criteria:

1. Relapsed or refractory Non-Hodgkin's lymphoma(NHL) patiens.
2. Eastern Cooperative Oncology Group(ECOG) score 0-2
3. Expected survival \>3 months
4. Measurable disease.

Exclusion Criteria:

1. Patients who needs treatment with immunosuppressive agents
2. Hematosepsis or Uncontrolled active infection
3. History of epilepsy or other CNS disease.
4. Active hepatitis B , hepatitis C or HIV infection or any other uncontrolled active infection.
5. Pregnancy or breast-feeding women.
6. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial.
7. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluatio

Primary outcomes:
measure: OS
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Peking
country: China
facility: Peking university third hospital
state: Beijing
Study officials:
affiliation: Peking University Third Hospital
name: Hongmei Jing, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06913153: Tianjin Diabetes and Health Cohort Study
Official title: Tianjin Diabetes and Health Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus
Keywords: cohort study
diabets complication
etiology
clinical epidemiology
health economic evaluation
Lead sponsor: Tianjin Medical University
Sponsor class: OTHER
First posted: 2025-04-06
Enrollment: 396983
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study was conducted through the University-Enterprise Joint Laboratory for Diabetes Epidemiology Research at Tianjin Medical University, China. Longitudinal multi-source health big data from 2009 to 2024 (encompassing 396,983 individuals with diabetes treated in secondary and tertiary healthcare facilities in Tianjin) were integrated to establish a representative diabetes population cohort.

Brief summary: The goal of this observational study is to reveal the natural history of diabetes and the occurrence and development patterns of its complications, to evaluate the effectiveness of diabetes interventions, and to assess the health and medical burdens caused by diabetes in Tianjin, based on the medical records and health big data in Tianjin and correspondingly constructed diabetes-specific cohort.

Detailed description: This study was conducted through the University-Enterprise Joint Laboratory for Diabetes Epidemiology Research at Tianjin Medical University. Retrospective and ongoing medical records and health big data from 396983 diabetes patients treated in secondary and tertiary hospitals in Tianjin between 2009 and 2024 were collected to establish a diabetes population cohort. Using advanced data mining techniques, multi-dimensional data including electronic health records (EHRs), medical imaging data, and wearable device metrics were analyzed.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with diabetes
* Patients with three or more recorded visits
* The following information was complete at the first visit: age, sex, Blood Glucoseor ,glycated hemoglobin(HbA1c)

Exclusion Criteria:

* none

Primary outcomes:
measure: Diabetes Complications
timeFrame: Baseline and week 520
Secondary outcomes:
measure: Glycemic Control
timeFrame: baseline and week 520
measure: Death
timeFrame: baseline and week 520
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01839253: The Effect of Antihypertensive Agents Concerning With Hemodynamics and Reduction of Anaesthetics in Orthognathic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Orthognathic Surgery
Keywords: antihypertensive agents
hemodynamic
anesthetics reduction
orthognathic surgery
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2013-04-24
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: For those who receive hypotensive anesthesia in orthognathic surgeries, the investigators premedicate with anti-hypertensive agent so that it decreases the occurence of tachycardia and the rebound hypertension due to hypotensive anesthesia, enabling us to compare hemodynamic stability and reduction of anesthetic agents during the operation.


Eligibility criteria: Inclusion Criteria:

1. ASA class I-II
2. obtaining written informed consent from the parents
3. aged 18-29 years who were undergoing orthognathic surgery.

Exclusion Criteria:

1. Hypertension patients with anti-hypertensive agents
2. chronic renal failure or End stage renal disease patients.
3. renal artery stenosis history.
4. Patients who are with medication due to systemic disease.
5. symptomatic asthma
6. Drug hyperactivity
7. neurological or psychiatric illnesses
8. mental retardation
9. patients who can't read the consent form due to illiterate or foreigner

Primary outcomes:
measure: the influence of antihypertensive agents on hemodynamic stability
timeFrame: From the beginning until the end of hypoetensive anesthesiaan expected average of 65 mins.(From manipulration of Mandible to maxilla)
Secondary outcomes:
measure: reduction of anaesthetics with control
timeFrame: From the beginning until the end of hypoetensive anesthesia an expected average of 65 mins.(From manipulration of Mandible to maxilla)
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine
Study officials:
References:
Clinical trial NCT00346853: Phase 1 Pilot Study of 4-MP to Treat Stargardt Macular Dystrophy
Official title: Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Macular Dystrophy, Corneal
Keywords: Dark adaptation inhibition
Stargardt macular dystrophy
4-Methylpyrazole (4-MP)
Antizol
Fomepizole
Lead sponsor: University of Utah
Sponsor class: OTHER
First posted: 2006-06-30
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate whether taking 4-methylpyrazole (4-MP, fomepizole, Antizol™) inhibits dark adaptation of the eye. In other words, we are testing if 4-MP slows the processing of vitamin A derivatives in the eye. By slowing down these processes, individuals with Stargardt disease may have better chances of saving their remaining vision. 4-MP has been shown to slow dark adaptation in animals, and is FDA approved for human use to treat individuals with methanol or ethylene glycol (antifreeze) poisoning by shutting down the body's ability to process alcohols. This medication has an excellent safety profile and has been reported to have no short-term or long-term side effects, as long as patients refrain from any alcohol while the medication is in the body. A single dose of 4-MP remains in the body for about 12 hours, and therefore, it may inhibit dark adaptation of your eyes for up to 12 hours. Studying the effects of 4-MP may lead to effective medical treatment to save Stargardt patients' vision, and may also have similar effects in other macular degenerative diseases.


Eligibility criteria: Inclusion Criteria:

* All nonpregnant, nonlactating adults with normal vision in both eyes

Exclusion Criteria:

* Previous ocular pathologies

Primary outcomes:
measure: Dark adaptation inhibition measured 30 minutes after drug infusion using Goldman-Weeker adaptometer.
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Moran Eye Center, University of Utah
state: Utah
Study officials:
affiliation: University of Utah
name: Paul S Bernstein, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jurgensmeier C, Bhosale P, Bernstein PS. Evaluation of 4-methylpyrazole as a potential therapeutic dark adaptation inhibitor. Curr Eye Res. 2007 Oct;32(10):911-5. doi: 10.1080/02713680701616156.
Clinical trial NCT02588053: Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Official title: Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Multiple Sclerosis
Lead sponsor: University of Colorado, Denver
Sponsor class: OTHER
First posted: 2015-10-27
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Relapsing Multiple Sclerosis and Healthy Controls

Brief summary: Primary Aims: To determine how effective long term Natalizumab (NTZ) therapy is in slowing the progression of whole brain atrophy. Whole brain atrophy rates will be measured through magnetic resonance imaging (MRI) scans and compared between patients with Multiple Sclerosis (MS) who have been using NTZ for at least 2 years versus age and gender-matched healthy controls. The primary outcome will be whole brain atrophy rate measured as the percent change in brain volume (PBVC) over a two-year period.

Primary hypothesis:

The investigators hypothesize that long term (\>2 years) NTZ therapy will slow the rate of whole brain atrophy in patients with Multiple Sclerosis (MS) (as measured by percent change in brain volume), reaching a whole brain atrophy rate similar to that of non-MS controls (a true "disease activity free" state).


Eligibility criteria: Inclusion Criteria:

* 18-55 inclusive years of age at the time of informed consent
* Diagnosis of relapsing multiple sclerosis as defined by the 2010 revised McDonald criteria
* Currently taking Tysabri

Exclusion Criteria:

* Systemic steroid users
* comorbidities that could confound MRI outcomes

Primary outcomes:
measure: Change in Brain Atrophy Rate
timeFrame: Baseline, Year 1, and Year 2
Secondary outcomes:
measure: Change in Mean Cortical Thickness
timeFrame: Baseline, Year 1, and Year 2
measure: Change in Neocortical Gray Matter Volume
timeFrame: Baseline, Year 1, and Year 2
measure: Change in Subcortical Gray Matter Volume
timeFrame: Baseline, Year 1, and Year 2
Other outcomes:
measure: Change in Patient-reported Quality of Life
timeFrame: Baseline, Year 1, and Year 2
Locations:
city: Aurora
country: United States
facility: University of Colorado Anschutz
state: Colorado
Study officials:
affiliation: University of Colorado, Denver
name: Augusto Miravalle, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01122953: Bioequivalence Study Of PHENYTOIN Suspension Made By Pfizer, Versus EPAMIN® Made By McNeil LA LLC In Healthy Volunteers Under Fasting Conditions
Official title: Bioequivalence Study Of 5ml Dose Of PHENYTOIN 125mg/ 5ml Suspension Made By Laboratorios Pfizer, S.A. De C.V. Versus EPAMIN® 125 mg/5ml Made By McNeil LA LLC, Study In Healthy Volunteers Under Fasting Conditions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: Bioequivalence
EPAMIN
PHENYTOIN
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2010-05-13
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: To investigate the bioequivalence between two compounds (phenytoin and epamin) by a randomized, single dose study under fasting conditions in healthy volunteers.

Detailed description: Bioequivalence study in healthy volunteers

Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 18 and 55 years
* Body Mass Index (BMI) of 18 to 26.9 kg/m2 or ± 10% variation of the ideal weight; and a total body weight \>50 kg (110 lbs).
* An informed consent document signed and dated by the subject or a legally acceptable representative.

Exclusion Criteria:

* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
* Any condition possibly affecting drug absorption (eg, gastrectomy).
* A positive urine drug screen.

Primary outcomes:
measure: Area under the curve (AUC): The AUC from administration to the last sampling time will be determined by the trapezoid method.
timeFrame: 0-168 h
measure: Maximum Concentration (Cmax): The maximum plasmatic concentration (Cmax) will be obtained as the highest concentration observed in the sampling interval.
timeFrame: 0-168 h
measure: Time maximum concentration (tmax) is observed. Will be reported as the time at which the maximum concentration is observed.
timeFrame: 0-168 h
Secondary outcomes:
measure: Constant of elimination (ke): Will be determined as the slope from the linear logarithmic regression of the terminal phase of the logarithmic graph of concentration over time.
timeFrame: 0-168 h
Other outcomes:
Locations:
city: Mexico
country: Mexico
facility: Pfizer Investigational Site
state: Distrito Federal
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT00383253: Methods Study to Characterize Early Indicators of Weight Loss in People
Official title: A Randomized, Open-Label, Parallel Group, Fixed Energy Deficit Methodology Trial to Characterize Early Efficacy Biomarkers During Treatment of Obesity in Adult, Obese, Male Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
Collaborators: name: University of Adelaide
name: Royal Adelaide Hospital
First posted: 2006-10-03
Enrollment: 57
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Methods study to characterize early indicators of weight loss in people.


Eligibility criteria: Inclusion Criteria:

* Subjects \>=18 years of age with BMI \>= 30 and \< 40 kg/m2

Exclusion Criteria:

* Females, those with illnesses expected to cause weight loss, those without stable body weight within 3 months of screening.

Primary outcomes:
measure: To evaluate the effect of varying degrees of controlled, 1-month, caloric restriction on weight loss, and response of known circulating, candidate biomarkers
timeFrame: Throughout trial
Secondary outcomes:
measure: To evaluate the time course, magnitude and biomarkers of metabolic compensation as well as assessment of well being (via questionnaires) following varying degrees of controlled, 1-month, caloric restriction
timeFrame: Throughout trial
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: Pfizer Investigational Site
state: South Australia
city: North Adelaide
country: Australia
facility: Pfizer Investigational Site
state: South Australia
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04729153: Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity
Official title: Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-01-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Retrospective study

Brief summary: Evaluate effect of DAADs on covid-19 disease.

Detailed description: If Chronic HCV patients who already received DAADs are protected against covid 19 and considered to be immune or not And if DAADS can be used in ttt of covid 19

Eligibility criteria: Inclusion Criteria:

1. HCV patient with or without LC.
2. \>18 years old.
3. Received DAADs at 2019.

Exclusion Criteria:

1. Combined HCV and HIV infected patients.
2. Combined HCV and HBV infected patients.
3. \< 18 years old.
4. Pregnant or breast-feeding patients.
5. Patients with autoimmune disease.
6. Patients with multiorgan failure, active cancer, renal insufficiency.
7. Patients received immunosuppressive drugs.
8. Immune compromised patients.
9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.

Primary outcomes:
measure: Evaluate the effect of DAADs on covid -19
timeFrame: 12 months (from 1/2/2021 to 1/2/2022)
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00960453: Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin
Official title: Multiple-dose, Dose Escalation Study to Investigate the Pharmacokinetics/Pharmacodynamics of Sitagliptin in Healthy Male Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Diabetes Mellitus
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2009-08-17
Enrollment: 12
Sex: MALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of sitagliptin in healthy volunteers.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects aged 20 - 50 years
* A body mass index (BMI) in the range 17-28 kg/m2
* Fasting plasma glucose levels in the range 70-110 mg/dL
* Sufficient ability to understand the nature of the study and any hazards of participating in it
* Provide written informed consent after being fully informed about the study procedures

Exclusion Criteria:

* Presence or history of severe adverse reaction to any drug (e.g., sitagliptin) or a history of severe allergic disease
* Clinically relevant abnormal medical history that could interfere with the objectives of the study
* A subject who has the following screening laboratory test results; creatinine clearance (calculated by Cockcroft-Gault equation) \< 80 mL/min
* History of gastrointestinal disease or surgery (except simple appendectomy or repair of hernia), which can influence the absorption of the study drug
* A subject whose SBP is over 150 mmHg or below 100 mmHg and DBP is over 95 mmHg or below 65 mmHg
* Presence or history of drug abuse
* Participation in other clinical trial within 2 months
* Use of a prescription medicine, herbal medicine within 2 weeks or over-the-counter medication within 1 week before first dose
* Blood donation during 2 months or apheresis during 1 month before the study
* Presence or history of alcohol abuse
* Users of nicotine-containing substances within the previous three months
* Use of grapefruit juice, alcohol or smoking during restriction period
* Subject judged not eligible for study participation by investigator

Primary outcomes:
measure: To evaluate the pharmacokinetics after repeated administrations of sitagliptin 25, 50 and 100 mg
timeFrame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours after drug administration
measure: To evaluate the pharmacodynamics (activity of Dipeptidyl peptidase-IV enzyme) after repeated administrations of sitagliptin 25, 50 and 100 mg
timeFrame: Pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48 hours after drug administration
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Clinical Trials Center; Seoul National University Hospital
Study officials:
affiliation: Seoul National University College of Medicine and Hospital
name: Kyung-Sang Yu, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: